Skip to main content
Log in

Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas

  • Original Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

We performed a prospective study to evaluate the imaging potential of thallium-201 as compared with other imaging modalities in differentiating residual/re-current tumors from post-therapy changes in patients with musculoskeletal sarcomas.201TI scans, magnetic resonance imaging (17), X-ray computed tomography (6) or contrast angiography (6) studies in 29 patients previously treated for musculoskeletal sarcomas were correlated with either histopathologic findings (26 patients) or 2-year clinical follow-up (three patients). All imaging studies were acquired within 2 weeks. Ratios of201T1 tumor uptake to the contralateral (28 patients) or adjacent region of interest were calculated. When qualitative interpretation was in doubt, only those cases with a ratio of 1.5 or more were considered suggestive of recurrent or residual viable tumor tissue. Residual or recurrent tumor tissue was verified in 21 patients by biopsy. All had true-positive201Tl scans while the other imaging modalities were true-positive in 20 and equivocal in one. In eight patients, there was no evidence of viable tumor tissue as proven by biopsy in five and long-term clinical follow-up in three.201Tl scan was false-positive (ratio 1.5) in one patient and true-negative in seven while the other' imaging modalities had four false-positives. The average201T1 ratios were 3.8±1.1 in the true-positive cases and 1.3±0.3 in the true-negative cases. The percentage sensitivities, specificities, and accuracy for201T1 were 100%, 87.5%, and 96.5% versus 95%, 50%, and 82.7% respectively for other imaging modalities These results indicate that201T1 scintigraphy is more accurate than other imaging modalities in differentiating residual/recurrent musculoskeletal sarcomas from post-therapy changes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Aisen AM, Martel W, Braunstein EM, et al. MRI and CT evaluation of primary bone and soft-tissue tumors.AJR 1986; 146: 749.

    Google Scholar 

  2. Hudson TM, Hamlin DJ, Enneking WF, et al. Magnetic resonance imaging of bone and soft-tissue tumors: early experience in 31 patients compared with computed tomography.Skeletal Radiol 1985; 13: 134–136.

    Google Scholar 

  3. Petasnick J, Turner D, Charters J, et al. Soft-tissue masses of the locomotor system: comparison of MR imaging with CT.Radiology 1986; 160: 125–133.

    Google Scholar 

  4. Ramannah L, Waxman AD, Weiss A, Rosen G. Thallium-201 (Tl-201) scan patterns in bone and soft tissue sarcoma [abstract].J Nucl Med 1992; 33: 843.

    Google Scholar 

  5. El-Gazzar AH, Malkì A, Abdel-Dayem HM, et al. Role of Tl201 in the diagnosis of solitary bone lesions.Nucl Med Commun 1989; 10: 477–485.

    Google Scholar 

  6. Ramannah L, Waxman AD, Binney G, Waxman S, Mirra J, Rosen G. Tl-201 scintigraphy in bone sarcoma: comparison with Ga-67 and Tc-99m MDP in the evaluation of chemotherapeutic response.J Nucl Med 1990; 31: 567–571.

    Google Scholar 

  7. Kostakoglu L, Abdel-Dayem HM, Yeh SD, Larson SM. A comparative study of thallium-201, CT/MRI/angiography in bone and soft tissue sarcomas: correlation with histologic findings [abstract].J Nucl Med 1992; 33: 843.

    Google Scholar 

  8. Ganz WI, Nguyen TQ, Benedetto MP, et al. Use of early, late and SPECT thallium imaging in evaluating activity of soft tissue and bone tumors [abstract].J Nucl Med 1993; 34: 32P.

  9. Seeger LL, Widoff BE, Bassett LW Rosen G, Eckhardt JJ. Preoperative evaluation of osteosarcoma; value of gadopentetate dimeglumine-enhanced MR imaging.AJR 1991; 157: 347–351.

    Google Scholar 

  10. Kransdorf MS, Jelinek JS, Moser RP Jr, Utz JA, Brower AC, Hudson TM, Berrey BH. Soft tissue masses: diagnosis using MR imaging.AJR 1989; 153: 541–547.

    Google Scholar 

  11. Holscher HC, Bloem JL, Nooy MA, Taminiau AH, Zeulderik F, Hermans J. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas.AJR 1990; 154: 763–769.

    Google Scholar 

  12. Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy.Radiology 1992; 184: 234–238.

    Google Scholar 

  13. Dewhirst MW, Sostman HD, Leopold KA, et al. Soft-tissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring:Radiology 1990; 174: 847–853.

    Google Scholar 

  14. Lemmi MA, Fletcher BD, Marina NM, Slade W, Parham DM, Jenkins JJ, Meyer WH. Use of MR imaging to assess results of chemotherapy for Ewing sarcoma.AJR 1990; 155: 343–346.

    Google Scholar 

  15. Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation.AJR 1991; 157: 825–833.

    Google Scholar 

  16. Zlatkin MB, Lenkinski RE, Shinkwin M, Schmidt RG, Daly JM, Holland GA, Frank T, Kressel HY. Combined MR imaging and spectroscopy of bone and soft tissue tumors.J Comput Assist Tomogr 1990; 14: 1–10.

    Google Scholar 

  17. Marano I, Brunetti A, Covello M, Belfiore G, Giovine S, Salvatore M. Magnetic resonance in the diagnosis and follow-up of soft-tissue sarcomas.Radiolia Medica 1992; 84: 15–21.

    Google Scholar 

  18. Abdel-Dayem HM, Scott AM, Macapinlac HA, et al. In: Freeman LM, ed.Nuclear medicine annual. New York: Raven Press; 1994: 181–234.

    Google Scholar 

  19. Kern K, Brunetti A, Norton J, Chang A, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET.J Nucl Med 1988; 29: 181–186.

    Google Scholar 

  20. Griffeth L, Dehdashti F, McGuire A, et al. PET evaluation of soft-tissue masses with fluorine- 18-2-deoxy-d-glucose.Radiology 1992; 182: 185–194.

    Google Scholar 

  21. Adler L, Blair H, Makley J, et al. Noninvasive grading of musculoskeletal tumors using PET.J Nucl Med 1991; 32: 1508–1515.

    Google Scholar 

  22. Caner B, Kitapci M, Inlay M, et al. Technetium-99m-MIBI uptake in benign and malignant bone lesions: comparative study with technetium-99m-MDPJ Nucl Med 1992; 33: 319–324.

    Google Scholar 

  23. Choi H, Varma DG, Fornage BD, Kim EE, Johnston DA. Softtissue sarcoma: MR imaging vs sonography for detection of local recurrence after therapy.AJR 1991; 157: 353–358.

    Google Scholar 

  24. Venuta S, Ferraiuolo R, Morrone G, et al. The uptake of Tl201 in normal and transformed thyroid cell lines.J Nucl Med Allied Sei 1979; 23: 163–166.

    Google Scholar 

  25. Waxman AD. Thallium-201 in nuclear oncology. In: Freeman LM, ed.Nuclear medicine annual. New York: Raven Press; 1991: 193–209.

    Google Scholar 

  26. Sehweil A, McKillop JH, Ziada G, et al. The optimum time for tumor imaging with thallium-201.Eur J Nucl Med 1988; 13: 527–529.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kostakoglu, L., Panicek, D.M., Divgi, C.R. et al. Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas. Eur J Nucl Med 22, 1232–1237 (1995). https://doi.org/10.1007/BF00801605

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00801605

Key words

Navigation